Concepedia

Olaf Prien

OP

Statistics

Publications

9

Citations

401

H-Index

9

Active since

1997

Affiliations

Bayer (Germany)(Current)

Orion Corporation (Finland)

Olaf Prien is an author at Bayer (Germany) specializing in pharmacology, pharmacy, and drug disposition.

Publications per year

1997–2021

9

Publications

9

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

Christian Zurth, Mikko Koskinen, Robert E. Fricke et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2019 · 102 citations · Full text

, , +17

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

Neal D. Shore, Christian Zurth, Robert E. Fricke et al. · Targeted Oncology · 2019 · 94 citations · Full text

, , +17

From the Insoluble Dye Indirubin towards Highly Active, Soluble CDK2‐Inhibitors

Rolf Jautelat, Thomas Brumby, Martina Schäfer et al. · ChemBioChem · 2005 · 81 citations · Full text

, , +11

3,3‘-Dipyridyl BINOL Ligands. Synthesis and Application in Enantioselective Addition of Et<sub>2</sub>Zn to Aldehydes

Robert R. Milburn, Syed Muhammad Shakil Hussain, Olaf Prien et al. · Organic Letters · 2007 · 35 citations

, , +13

Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug–Drug Interaction Potential

Marcus‐Hillert Schultze‐Mosgau, Joachim Höchel, Olaf Prien et al. · Clinical Pharmacokinetics · 2018 · 30 citations · Full text

, , +13

1–5 of 9